Staphylococcus aureus vaccine for orthopedic patients: An economic model and analysis

被引：24

作者：

Lee, Bruce Y. ^{[1
,2
,3
]}

Wiringa, Ann E. ^{[2
,3
]}

Bailey, Rachel R. ^{[2
,3
]}

Lewis, G. Jonathan ^{[2
,3
]}

Feura, Jared ^{[2
,3
]}

Muder, Robert R. ^{[4
]}

机构：

[1] Univ Pittsburgh, Publ Hlth Computat & Operat Res PHICOR, Sect Decis Sci & Clin Syst Modeling, Pittsburgh, PA 15213 USA

[2] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA 15213 USA

[3] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA

[4] Univ Pittsburgh, Div Infect Dis, VA Pittsburgh Hlth Syst, Pittsburgh, PA 15213 USA

来源：

VACCINE | 2010年 / 28卷 / 12期

关键词：

Staphylococcus aureus; Vaccine; Orthopedic surgery; Economics; Computer simulation; POLYSACCHARIDE CONJUGATE VACCINE; QUALITY-OF-LIFE; PASSIVE-IMMUNIZATION; TOTAL HIP; MRSA; INFECTIONS; SURGERY; UTILITY; IMMUNOTHERAPY; ARTHROPLASTY;

D O I：

10.1016/j.vaccine.2009.12.075

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [<=$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy >= 30%, and a $100 vaccine at vaccine efficacy >= 70%. High MASA prevalence (>= 25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MASA prevalence and vaccine efficacies and costs. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：2465 / 2471

页数：7

共 42 条

[1] Antibiotic resistance in Staphylococcus aureus and its relevance in therapy [J].

Bal, AM ;

Gould, IM .

EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (13) :2257-2269

[2] A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin [J].

Benjamin, D. K., Jr. ;

Schelonka, R. ;

White, R. ;

Holley, H. P., Jr. ;

Bifano, E. ;

Cummings, J. ;

Adcock, K. ;

Kaufman, D. ;

Puppala, B. ;

Riedel, P. ;

Hall, B. ;

White, J. ;

Cotten, C. M. .

JOURNAL OF PERINATOLOGY, 2006, 26 (05) :290-295

[3] Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model [J].

Bounthavong, M. ;

Hsu, D. I. ;

Okamoto, M. P. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (03) :376-386

[4] What does the value of modern medicine say about the $50,000 per Quality-Adjusted Life-Year decision rule? [J].

Braithwaite, R. Scott ;

Meltzer, David O. ;

King, Joseph T., Jr. ;

Leslie, Douglas ;

Roberts, Mark S. .

MEDICAL CARE, 2008, 46 (04) :349-356

[5]

*CPT, 2009, COD REL VAL SEARCH

[6] Antistaphylococcal vaccines and immunloglobulins - Current status and future prospects [J].

Deresinski, Stan .

DRUGS, 2006, 66 (14) :1797-1806

[7] Health-related quality of life in total hip and total knee arthroplasty - A qualitative and systematic review of the literature [J].

Ethgen, O ;

Bruyere, O ;

Richy, F ;

Dardennes, C ;

Reginster, JY .

JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2004, 86A (05) :963-974

[8]

Fattom A, 2004, VACCINE, V23, P656, DOI 10.1016/j.vaccine.2004.06.043

[9] Development of StaphVAX™, a polysaccharide conjugate vaccine against S-aureus infection:: from the lab bench to phase III clinical trials [J].

Fattom, AI ;

Horwith, G ;

Fuller, S ;

Propst, M ;

Naso, R .

VACCINE, 2004, 22 (07) :880-887

[10] Colonization with methicillin-resistant Staphylococcus aureus in ICU patients:: Morbidity, mortality, and glycopeptide use [J].

Garrouste-Orgeas, M ;

Timsit, JF ;

Kallel, H ;

Ali, AB ;

Dumay, MF ;

Paoli, B ;

Misset, B ;

Carlet, J .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2001, 22 (11) :687-692

← 1 2 3 4 5 →